Doxorubicin plus Ifosfamide as Salvage Treatment for Patients with Advanced Breast Cancer Refractory to Epirubicin plus Cyclophosphamide

被引：0
作者：
Aristidis Polyzos
C. Kosmas
N. Tsavaris
C. Markopoulos
N. Kalahanis
O. Papadopoulos
T. Arnaouti
P. P. Sfikakis
机构：
[1] Athens University School of Medicine,First Department of Propaedeutic Medicine
[2] Laikon Hospital,Medical Oncology Unit
[3] Goudi,Department of Pathophysiology
[4] Helena Venizelou Hospital,Department of Surgery
[5] Athens University School of Medicine,undefined
[6] Laikon Hospital,undefined
[7] Athens University School of Medicine,undefined
[8] Laikon Hospital,undefined
来源：
Clinical Drug Investigation | 2000年 / 19卷
关键词：
Breast Cancer; Paclitaxel; Doxorubicin; Epirubicin; Advanced Breast Cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: To investigate the response and toxicity of a salvage regimen in patients with advanced breast cancer whose tumours became resistant to fluorouracil-epirubicin-cyclophosphamide (FEC). By substituting doxorubicin for epirubicin and ifosfamide for cyclophosphamide, we aimed to evaluate the possible lack of cross-resistance between the two anthracyclines and the two alkylating agents.
引用
收藏
页码：349 / 355
页数：6
相关论文
共 79 条
[1]  
Brambilla C.(1986)Phase II study of doxorubicin versus epirubicin in advanced breast cancer Cancer Treat Rep 70 261-6
[2]  
Rossi A.(1988)Prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin J Clin Oncol 6 967-88
[3]  
Bonfante V.(1988)Phase III randomized study of fluorouracil, epirubicin and cyclophosphamide versus fluorouracil, doxorubicin and cyclophosphamide in advanced breast cancer: an Italian multicentre trial J Clin Oncol 6 976-82
[4]  
Ahmann D.L.(1974)Phase II clinical trial of isophosphamide (NSC-109724) in patients with advanced breast cancer Cancer Chemother Rep 6 861-5
[5]  
Bisel H.F.(1976)Further experience with isophosphamide Cancer Treat Rep 7 955-7
[6]  
Hahn R.G.(1988)Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer J Cancer Res Clin Oncol 114 602-4
[7]  
Falkson G.(1989)Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells Cancer Res 49 511-5
[8]  
Falkson H.C.(1989)The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo Biochem Pharmacol 38 1835-40
[9]  
Steger G.G.(1958)Non-parametric estimations from incomplete observations J Am Stat Assoc 53 457-9
[10]  
Dittrich C.(1995)Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines J Natl Cancer Inst 87 1169-75
12345678